Validation and Clinical Utility of a 70-Gene Prognostic Signature for Women With Node-Negative Breast Cancer

Marc Buyse(Institut des Arts de Diffusion), Martine Piccart(Université Libre de Bruxelles)

JNCI Journal of the National Cancer Institute

September 5, 2006

10.1093/jnci/djj329

Cited by 1,226

Related Papers

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

|The Lancet|2014|4.7k

3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)

|Annals of Oncology|2016|2.1k

70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer

|New England Journal of Medicine|2016|2k

Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015

|Annals of Oncology|2015|1.8k

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial

|The Lancet|2007|1.5k